GI
BMY.RT

GS Investments’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

GS Investments’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,950
Closed -$9K – 133
2020
Q4 		$9K Buy
+12,950
New +$27.6K 0.01% 104
2020
Q3 		– Sell
-20,950
Closed -$75K – 122
2020
Q2 		$75K Hold
20,950
– – 0.06% 75
2020
Q1 		$79.6K Buy
+20,950
New +$69K 0.08% 70

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

GS Investments's BMY.RT Position: Q1 2021 in Review

GS Investments sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 12,950 shares — an estimated $9K sold.

GS Investments first reported a position in BMY.RT in Q1 2020 and held it in 3 quarters. The position peaked at $79.6K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • GS Investments reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • GS Investments sold 12,950 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $9K.
  • GS Investments first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 3 quarters.
  • GS Investments's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $79.6K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on GS Investments's 13F filing for Q1 2021, filed 7 May 2021.